MPWT
NRIX icon

MassMutual Private Wealth & Trust’s Nurix Therapeutics NRIX Stock Holding History

MassMutual Private Wealth & Trust’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.75K Hold
72
– – ﹤0.01% 2041
2026
Q1 		$1.12K Hold
72
– – ﹤0.01% 2115
2025
Q4 		$1.37K Buy
+72
New +$1.03K ﹤0.01% 2084

Other funds holding NRIX

Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
TM
Torren Management San Diego, California $197M AUM
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

MassMutual Private Wealth & Trust's NRIX Position: Q2 2026 in Review

MassMutual Private Wealth & Trust held its Nurix Therapeutics (NRIX) position steady in Q2 2026 at 72 shares worth $1.75K. The position accounts for ﹤0.01% of the portfolio, ranked #2041.

MassMutual Private Wealth & Trust first reported a position in NRIX in Q4 2025 and has held it in 3 quarters since. 10 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • MassMutual Private Wealth & Trust held 72 shares of Nurix Therapeutics worth $1.75K as of Q2 2026.
  • MassMutual Private Wealth & Trust left its Nurix Therapeutics share count unchanged in Q2 2026.
  • Nurix Therapeutics made up ﹤0.01% of MassMutual Private Wealth & Trust's portfolio in Q2 2026, its #2041 holding.
  • MassMutual Private Wealth & Trust first reported a position in Nurix Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 10 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on MassMutual Private Wealth & Trust's 13F filing for Q2 2026, filed 2 Jul 2026.